

🔥 Saamya Biotech (India) Ltd.

CIN: L24239AP2002PLC039449

August 14, 2018

To

Corporate Relations Department, BSE LTD, P J Towers, Dalal Street, Mumbai - 400001.

Sirs,

Sub: Q1 Unaudited Financial Results - Reg...


Ref: Scrip Code – 532905

Please find herewith attached Un-audited financial results for the first quarter ending 30th June 2018 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMITED

Director





Saamya Biotech (India) Ltd.

	Statement of Up Audited Park of Up	NDIA) LIMITED				
S.No.	Particulars Statement of Un-Audited Results for the Quarter ended 30.06.2018					
	•	For the	For the	For the		For the year
				Quarter		ended
. I.	Revenue from Operations	30.06.2018	31.03.2018	30.06.20	17	31.03.2018
II.	Other Income .		-		-	
III.	Total income (I+II)	-	-		-	
IV.	Expenses	-	-			
	(a) Cost of Materials consumed				-	
	(b) Purchase of stock-in-trade	-	-			
	(c) Changes in inventories of finished goods, work-in-progress	-	-			
	(d) Employee benefits expense	-	-		-	
	(e) Finance Cost	0.36	0.43		0.56	2
	(f) Depreciation and amortisation expense	-			-	
	(h)Other expenses	-	-		-	
	Total Expenses	0.25	0.25		0.25	1
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	0.61	0.68		0.81	3
VI.	Exeptional Items	(0.61)	(0.68)		(0.81)	(3.0
VII	Profit / (Loss) from before tax (V-VI)	(0.51)	-			
VIII.	Tax expense	(0.61)	(0.68)		(0.81)	(3.0
	Current Tax					
	Deferred Tax	-	-			
IX.	Net Profit / (Loss) after Tax (VII-VIII)	(0.61)	(0.60)			
X	Other Comprehensive Inocme	(0.01)	(0.68)		(0.81)	(3.0
	Items that will not be reclasified to Profit or Loss	_				
]	Items that will be reclasified to Profit or Loss		-			
XI	Total Comprehensive Income	(0.61)	(0.68)		(0.01)	
XII	Paid-up equity share capital	(0.01)	(0.03)		(0.81)	(3.0
((Face Value of Rs. 10/- per share)	2,488.25	2,488.25	2	488.25	2 400
XIII	Earnings Per Equity Share of face value of Rs.10/- each)	_,	2,400.23	2)-	100.25	2,488.
	a) Basic & Diluted (In Rs.)	(0.00)	(0.00)		(0.00)	(0.0
- 1		()	(0.00)		(0.00)	(0.0)

NOTES:

1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.08.2018

- 2 These results have been prepared in accordance with the recognition and measurent principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with teh relevant rules issued thereunder and other accouting propouncements generally accepted in India.
- The Company is engaged in "Research and Development of Bio-technology Products" operating hence there are no separate reportable segments as per Ind AS -108

For SAAMYA BIOTECH (INDIA) LIMITED

MANIVARDHAN REDDY YALA **Wholetime Director** Din (01368438)

Place: Hyderabad Date: 14.08.2018

DTECA

Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel +91-40-2355 1601 / 1604. Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241 Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com



Phone: 040-23418836

040-40272617

Mobile: 98482 71555

LIMITED REVIEW REPORT

To, The Board of Directors, SAAMYA BIOTECH (INDIA) LTD

We have reviewed the accompanying statement of Un-audited Financial Results of SAAMYA BIOTECH (INDIA) LTDfor the quarter ended 30thJune, 2018 attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 14th August, 2018. For M M Reddy & Co. Chartered Accountants

M. Madhusudhana Raddichartered

Membership No. 2